XunJing BioSecures Tens of Millions RMB in Angel Funding to Build an Innovative Small Molecule Drug Discovery Platform Targeting RNA

VCBeat learned at the first time,Xungene Therapeutics (Beijing) Intelligent Technology Co., Ltd. (referred to as "Xungene Therapeutics")Xungene Therapeutics Announces Completion of Tens of Millions of RMB in Angel Round Financing. This round of financing was led by Shenzhen CO-WIN Venture CAPITAL Investment Limited, with participation from VCBeat Tianji Fund, Innocore (Beijing) Investment Management Co., Ltd, and Tsinghua Alumni Fund. The funds will be used for the establishment and enhancement of the company’s R&D platform, as well as the research and development of its first batch of self-developed pipelines.

In recent years, with the explosion of in vivo RNA structure detection technology and artificial intelligence technology, the research and development of small molecule drugs targeting RNA has become a new blue ocean. It is an emerging and novel pharmaceutical direction that has risen rapidly in recent years, with broad market prospects and tremendous development potential.

Xungene Therapeutics was founded in 2023 by Professor Zhang Qiangfeng from the School of Life Sciences at Tsinghua University and Professor Wang Yangming from the Academy for Advanced Technology at Peking University. The founding team, led by these experts, all hold doctoral degrees in relevant fields. The company aims to develop small-molecule drugs targeting RNA, focusing on rare diseases and cancer as its initial areas. Utilizing proprietary RNA structure detection and artificial intelligence technologies, the company designs, screens, and evaluates small-molecule drugs in a more efficient and intelligent manner, shortening the R&D cycle, improving development efficiency, and accelerating the drug's path to market.

Currently, the company has successfully built three world-leading technology platforms (RNA Structure Data Platform, Small Molecule High-Throughput Screening Platform Targeting RNA, and AI Computational Platform for RNA-Small Molecule Interactions) and, based on these, started to advance several proprietary drug development pipelines. At the same time, Xungene Therapeutics is also committed to serving domestic and international partners engaged in nucleic acid drug research and development with its top-tier platforms. Leveraging Xungene Therapeutics' extensive expertise and innovative technologies in the RNA field, the company aims to accelerate the research and technological transformation of RNA-related drugs.

Xungene Therapeutics' Technical Planning Blueprint

Founders of Xungene Therapeutics: Zhang Qiangfeng and Dr. Wang YangmingExpressed: Deep gratitude to the investors for their generous love and support. Xungene Therapeutics will repay all friends and sectors of society with continuous innovation and solid work. We are committed to serving national health and strengthening technological power through high-tech transformation, developing original drugs to save patients' lives, and striving to achieve our grand vision of "Ultimate Innovation, Better World."

Mr. Xi Yanbin, Partner of CO-WIN Healthcare Fund (Beijing)Targeted RNA small molecule drugs offer a broader selection of targets, providing new solutions for undruggable targets. With the rapid advancement in RNA structure detection technology, affinity screening technology, and AI technology, targeted RNA small molecule drugs are expected to flourish. The founding team has deep expertise in RNA structural biology, RNA molecular biology, and AI, holding a leading position globally. We look forward to Xungene Therapeutics making new breakthroughs in the field of targeted RNA drugs.

Li Zhu, Founding Partner of Innocore (Beijing) Investment Management Co., Ltd.Traditional drug development targeting proteins faces challenges of "undruggable" targets. Shifting the drug target to RNA and modulating RNA function via small molecules to target "undruggable" disease-causing genes could expand the range of drug targets by several orders of magnitude. Professors Zhang Qiangfeng and Wang Yangming, with combined expertise in AI large models, RNA structural analysis, and nucleic acid drug development, are focusing on pipelines for cancer, genetic disorders, and chronic diseases to address unmet clinical needs. Innocore highly values the collaboration between the two professors from Tsinghua and Peking University, leveraging AI to empower small molecule-targeted RNA drug development, filling the drug gap for multiple diseases, and benefiting more patients.

Jiang Mingyue, General Partner of VCBeat Tianji FundRepresentation: The first development group focuses on the front-end link of scientific and technological innovation from "0" to "1", promoting the transformation and implementation of major scientific and technological achievements at home and abroad. Small molecule drugs targeting RNA have broad target selection space and promising application prospects in various disease fields. The founding team of Xungene Therapeutics has a composite background and profound technical accumulation. The first development group looks forward to joining hands with Xungene Therapeutics to promote the accelerated development of small molecule drugs targeting RNA.

Du Yan, Founding Partner of Shuimu Tsinghua Alumni FundRepresentation: The project founder is a top scientist in the industry. Professor Zhang Qiangfeng has an interdisciplinary background with dual doctorates in computer science and biology. He has been collaborating with Professor Wang Yangming for many years, forming a complementary and默契 partnership. Small molecule drugs targeting RNA have extensive clinical demand and, compared to protein targets, hold immense potential and opportunities. Technology platforms such as predictive analysis and artificial intelligence are advanced and innovative, leading both domestic and international competitors. We are full of anticipation and confidence in the development of Xungene Therapeutics.